Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Up 247.6% in October

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 65,700 shares, a growth of 247.6% from the October 15th total of 18,900 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 42,500 shares, the short-interest ratio is presently 1.5 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC grew its stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 516,000 shares of the company’s stock after acquiring an additional 126,000 shares during the period. Armistice Capital LLC owned 9.43% of Hepion Pharmaceuticals worth $526,000 at the end of the most recent quarter. Institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Trading Down 6.4 %

Shares of NASDAQ HEPA traded down $0.04 during mid-day trading on Tuesday, reaching $0.63. 32,419 shares of the company’s stock were exchanged, compared to its average volume of 86,268. Hepion Pharmaceuticals has a twelve month low of $0.55 and a twelve month high of $4.47. The business has a fifty day simple moving average of $0.67 and a 200 day simple moving average of $0.89. The firm has a market capitalization of $3.63 million, a price-to-earnings ratio of -0.10 and a beta of 1.81.

Hepion Pharmaceuticals (NASDAQ:HEPA) last released its earnings results on Tuesday, August 13th. The company reported ($0.68) earnings per share for the quarter.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.